Teva Pharmaceutical Industries (NYSE:TEVA) Issues FY 2026 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.570-2.770 for the period, compared to the consensus estimate of 2.660. The company issued revenue guidance of $16.4 billion-$16.8 billion, compared to the consensus revenue estimate of $16.5 billion.

Analyst Ratings Changes

Several research firms have commented on TEVA. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Friday, January 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Scotiabank lifted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th. Finally, Jefferies Financial Group boosted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $39.22.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA traded down $0.35 on Thursday, hitting $35.03. The stock had a trading volume of 11,965,792 shares, compared to its average volume of 8,265,040. The company has a market capitalization of $40.28 billion, a price-to-earnings ratio of 29.19, a price-to-earnings-growth ratio of 2.75 and a beta of 0.76. Teva Pharmaceutical Industries has a 52-week low of $14.99 and a 52-week high of $37.35. The firm has a 50-day moving average of $31.14 and a 200-day moving average of $29.29. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $3.98 billion for the quarter. Equities analysts expect that Teva Pharmaceutical Industries will post 2.6 EPS for the current year.

Insider Buying and Selling

In other news, insider Mark Sabag sold 62,102 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $30.14, for a total value of $1,871,754.28. Following the transaction, the insider owned 224,940 shares of the company’s stock, valued at $6,779,691.60. This represents a 21.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Eliyahu Sharon Kalif sold 345,810 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the sale, the executive vice president directly owned 57,478 shares of the company’s stock, valued at $1,933,559.92. This represents a 85.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 920,901 shares of company stock valued at $30,056,789 in the last 90 days. 0.54% of the stock is owned by company insiders.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 results beat expectations — Teva reported Q1 revenue of ~$3.98B and EPS of $0.53 (beat), driven by growth in branded drugs including Austedo, Ajovy and Uzedy, which underpinned the recent rally. TEVA Q1 Earnings Top Estimates
• Positive Sentiment: Acquisition expands growth pipeline — Teva agreed to acquire Emalex Biosciences (deal reported up to ~$900M) for ecopipam, a late?stage, NDA?ready Tourette therapy that complements Teva’s neuroscience franchise and supports near? and long?term growth. Teva to Acquire Emalex Biosciences
• Positive Sentiment: Analysts raising targets — Truist raised its price target to $45 (buy) and Piper Sandler reaffirmed overweight and lifted its target to $42, signaling continued analyst confidence and providing upside support for the stock. Truist price target raise Piper Sandler reaffirmation
• Positive Sentiment: Institutional interest and financing activity — Coverage pieces flagged a meaningful financing/interest from Blackstone and elevated options activity (large call buying), suggesting buy?side conviction behind the move higher. Blackstone financing analysis
• Neutral Sentiment: Guidance updated but in line — Teva reiterated FY?2026 EPS guidance (roughly 2.57–2.77), broadly consistent with consensus, leaving room for execution to drive further upside. Q1 results & guidance
• Neutral Sentiment: Options flow — Unusually large call buying was reported, which can amplify intraday moves but is not a fundamental change to the company’s outlook.
• Negative Sentiment: Generics headwinds remain — Management flagged weaker generics performance (including lower lenalidomide generic revenue), a recurring pressure point that tempers the earnings beat and means continued execution is needed to sustain growth. Reuters: branded drugs drive results
• Negative Sentiment: Short?term profit?taking risk — After a multi?day ~10–12% run, some pullback is normal as traders book gains; that dynamic can outweigh fresh positive headlines in the near term.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently modified their holdings of TEVA. Rubric Capital Management LP raised its holdings in shares of Teva Pharmaceutical Industries by 1.8% during the 2nd quarter. Rubric Capital Management LP now owns 26,000,000 shares of the company’s stock valued at $435,760,000 after buying an additional 450,000 shares in the last quarter. State Street Corp grew its position in Teva Pharmaceutical Industries by 1.2% during the fourth quarter. State Street Corp now owns 17,348,809 shares of the company’s stock valued at $541,456,000 after acquiring an additional 198,558 shares during the last quarter. Duquesne Family Office LLC grew its position in Teva Pharmaceutical Industries by 3.9% during the third quarter. Duquesne Family Office LLC now owns 16,593,935 shares of the company’s stock valued at $335,197,000 after acquiring an additional 625,000 shares during the last quarter. Glenview Capital Management LLC grew its position in Teva Pharmaceutical Industries by 7.1% during the second quarter. Glenview Capital Management LLC now owns 15,824,223 shares of the company’s stock valued at $265,214,000 after acquiring an additional 1,045,582 shares during the last quarter. Finally, Viking Global Investors LP raised its stake in shares of Teva Pharmaceutical Industries by 15.4% during the second quarter. Viking Global Investors LP now owns 11,681,333 shares of the company’s stock worth $195,779,000 after acquiring an additional 1,555,855 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.